On Apr. 23, 2020, Caladrius Biosciences announced the FDA has authorized its investigational new drug application for the study of CLBS119, a CD34+ cell therapy for repair of COVID-19 induced lung damage. The study will target patients with severe SARS-CoV-2 infection that required ventilatory support due to respiratory failure.